Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)

被引:0
|
作者
Joseph Muenzer
Jaco Botha
Paul Harmatz
Roberto Giugliani
Christoph Kampmann
Barbara K. Burton
机构
[1] University of North Carolina at Chapel Hill,Department of Genetics
[2] Takeda Pharmaceuticals International AG,undefined
[3] UCSF Benioff Children’s Hospital Oakland,undefined
[4] UFRGS,undefined
[5] Medical Genetics Service,undefined
[6] HCPA,undefined
[7] and INAGEMP,undefined
[8] Johannes Gutenberg University,undefined
[9] Ann & Robert H. Lurie Children’s Hospital of Chicago,undefined
关键词
Mucopolysaccharidosis II; MPS II; Hunter syndrome; Lysosomal storage disease; Statistical modeling; Disease registry; Idursulfase; Enzyme replacement therapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 50 条
  • [1] Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)
    Muenzer, Joseph
    Botha, Jaco
    Harmatz, Paul
    Giugliani, Roberto
    Kampmann, Christoph
    Burton, Barbara K.
    ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)
  • [2] Evaluation of the long-term treatment effects of idursulfase using statistical modelling: Data from the Hunter Outcome Survey (HOS)
    Muenzer, Joseph
    Burton, Barbara K.
    Harmatz, Paul
    Botha, Jaco
    Kampmann, Christoph
    MOLECULAR GENETICS AND METABOLISM, 2019, 126 (02) : S103 - S104
  • [3] Long-term weekly dosing of idursulfase in the treatment of mucopolysaccharidosis II (MPS II, Hunter syndrome)
    Beck, M.
    Wraith, E.
    Muenzer, J.
    Giugliani, R.
    Harmatz, P.
    Eng, C. M.
    Vellodi, A.
    Martin, R.
    Ramaswami, U.
    Calikoglu, M.
    Vijayaraghavan, S.
    Puga, A. C.
    Ulbrich, B.
    Shinawi, M.
    Cleary, M.
    Wendt, S.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2007, 30 : 116 - 116
  • [4] Survival in idursulfase-treated and untreated patients with MPS II: Data from the Hunter Outcome Survey (HOS)
    Burton, Barbara K.
    Jego, Virginie
    Jones, Simon A.
    MOLECULAR GENETICS AND METABOLISM, 2016, 117 (02) : S31 - S31
  • [5] Clinical outcomes after 3 years of idursulfase treatment in patients with MPS II: data from the Hunter Outcome Survey (HOS)
    Giugliani, Roberto
    Scarpa, Maurizio
    Tylki-Szymanska, Anna
    Beck, Michael
    Jego, Virginie
    Muenzer, Joseph
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S56 - S56
  • [6] MULTIPLE OPERATIONS IN INDIVIDUALS WITH MUCOPOLYSACCHARIDOSIS TYPE II (MPS II): DATA FROM THE HUNTER OUTCOME SURVEY (HOS)
    Giugliani, R.
    Bodamer, O.
    Burton, B.
    De Meirleir, L.
    Harmatz, P.
    Jones, S.
    Lampe, C.
    Malm, G.
    Parini, R.
    Steiner, R.
    Mendelsohn, N.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2010, 33 : S128 - S128
  • [7] Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS)
    Burton, Barbara K.
    Jego, Virginie
    Mikl, Jaromir
    Jones, Simon A.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2017, 40 (06) : 867 - 874
  • [8] Hearing loss in patients with mucopolysaccharidosis II: Data from HOS - the Hunter Outcome Survey
    Keilmann, Annerose
    Nakarat, Todsaporn
    Bruce, Iain A.
    Molter, David
    Malm, Gunilla
    JOURNAL OF INHERITED METABOLIC DISEASE, 2012, 35 (02) : 343 - 353
  • [9] Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey
    Burton, Barbara K.
    Guffon, Nathalie
    Roberts, Jane
    van der Ploeg, Ans T.
    Jones, Simon A.
    MOLECULAR GENETICS AND METABOLISM, 2010, 101 (2-3) : 123 - 129
  • [10] The hunter outcome survey (HOS): A registry of mucopolysaccharidosis II patients
    Beck, Michael
    MOLECULAR GENETICS AND METABOLISM, 2007, 92 (04) : S28 - S28